NYBC Ventures

Based on our deep science and focused on patients in need.

Vitestro is a developer of innovative medical robotic devices focused on enhancing patient care through autonomous blood drawing technology. The company's flagship device employs multi-dimensional ultrasound detection to identify nerves and arteries, utilizing deep learning algorithms to minimize the risk of arterial complications during clinical procedures. This advancement aims to streamline the blood collection process in hospitals and clinical laboratories, ultimately enabling healthcare professionals to perform operations with greater precision and improve overall patient health outcomes.

Functional Fluidics Inc. is a Detroit-based company founded in 2014 that specializes in developing biomarkers and surrogate endpoints to measure thrombosis and adhesion formation in whole blood, particularly for sickle cell disease. The company offers a range of proprietary blood function assays designed to standardize the assessment of red blood cell health and individual patient responses. Its services include flow adhesion, mechanical fragility, adhesion characterization, and adhesion avidity. Additionally, Functional Fluidics provides contract research services, which encompass initial consultation, preclinical validation, patient selection, monitoring, and the development of companion diagnostics. Through its innovative assays and research services, the company aims to enhance patient care by providing objective data on red blood cell health to pharmaceutical, biotech, and academic research organizations.

ViTToria Biotherapeutics is a company focused on developing gene-edited cell therapies, specifically next-generation T-cell therapeutics that aim to address significant unmet medical needs. Utilizing its proprietary Senza5 Technology, ViTToria enhances the efficacy, safety, and overall utility of cell-based treatments in preclinical settings. The company's innovative approach seeks to lower dosing requirements, simplify preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. This technology enables medical practitioners to improve patient outcomes, positioning ViTToria Biotherapeutics as a pioneer in the advancement of cell therapy solutions.

Aronora is a translational biotechnology company focused on the early-stage commercial development of innovative biologic therapeutics. It specializes in creating recombinant monoclonal antibodies and enzymes aimed at treating blood clotting diseases. Aronora's product candidates are designed to prevent pathological thrombi while preserving hemostasis, addressing a critical need in the healthcare sector. By offering solutions that overcome the limitations of existing clot-busting and blood-thinning medications, the company aims to significantly reduce mortality rates associated with blood clotting disorders, potentially saving thousands of lives each year.

Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify rare diseases that share common biological mechanisms, allowing it to create novel therapeutics capable of treating multiple conditions with a single treatment. This approach not only enhances the potential for effective solutions but also provides pharmaceutical companies with opportunities to address several rare diseases simultaneously. By targeting a diverse array of conditions, Star Therapeutics strives to significantly improve the lives of millions of patients affected by these challenging health issues.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

HealthQuest Capital is a growth equity firm based in Redwood City, California, established in 2013. The firm specializes in investing in commercial-stage companies across various sectors of the healthcare industry, including medical devices, biopharmaceuticals, healthcare services, and healthcare information technology. HealthQuest Capital focuses on innovative companies that develop medical technologies, diagnostics, research tools, and digital health solutions, aiming to support advancements that improve healthcare delivery and outcomes. As a Registered Investment Adviser, the firm is committed to fostering growth in the healthcare sector through strategic investments.

KaloCyte Inc., established in 2016 and based in Baltimore, Maryland, is a pre-clinical stage healthcare biotechnology company focused on developing innovative solutions for life-threatening blood loss scenarios. The company's flagship product, ErythroMer, is an artificial red blood cell substitute designed to be dried and bio-inspired, intended for use when stored red blood cells are unavailable or undesirable. This product aims to address critical gaps in trauma care services by providing a demonstrated proof of concept for treating hemorrhage situations effectively.

STRM.BIO is a biotechnology company focused on advancing gene therapy through the innovative use of extracellular vesicles (EVs). By leveraging the natural properties of EVs, which can efficiently deliver nucleic acids and proteins, the company aims to establish a new class of therapeutics that enhance the effectiveness of existing treatments while simplifying the delivery process. STRM.BIO emphasizes safety and practicality in its approach, utilizing EVs as low-immunogenic carriers that can be mass-produced for commercial use. The company's mission is to fulfill the potential of gene therapy by providing patients with more effective and accessible treatment options.

Catena Biosciences is a biotechnology firm focused on advancing protein conjugation technology to address autoimmune disorders and other medical challenges. The company specializes in a method that facilitates the rapid and selective attachment of proteins, utilizing natural amino acids such as tyrosine and cysteine. This innovative approach allows researchers to develop novel therapeutics across various fields, including autoimmune disorders, oncology, and vaccine development. By streamlining the process of building biologic structures, Catena Biosciences aims to enhance medical research and contribute to the creation of effective treatments.

Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease.

Vega Therapeutics is a biotechnology startup in the clinical stages, dedicated to developing innovative treatments for rare blood disorders. The company focuses on addressing unmet medical needs in this area by creating novel, first-in-class therapies. Its research centers on a unique mechanism of action that targets Protein S, aiming to provide effective hemostatic therapies for patients suffering from various bleeding disorders. By concentrating on these overlooked conditions, Vega Therapeutics aspires to improve the quality of life for individuals affected by these challenges.